ABT-450: Additional Phase IIb data
Additional data from the open-label, international Phase IIb Aviator (Study M11-652) trial in 571 patients with HCV genotype 1 infection showed that 97.5% of treatment-naïve patients (n=79) and 93.3% of null responders (n=45) who received ABT-450 plus ritonavir, ABT-267, ABT-333 and ribavirin for 12 weeks achieved an SVR 12 weeks after the end of treatment. Additionally, 87.5% of treatment-naïve patients who received ABT-450 plus ritonavir, ABT-267, ABT-333 and ribavirin for 8 weeks achieved an SVR12 (n=80). In treatment-naïve patients, SVR12 rates for other 12-week ABT-450 regimens were 85.4% for ABT-450 plus ritonavir, ABT-333 and ribavirin (n=41); 89.9% for ABT-450 plus ritonavir, ABT-267 and ribavirin (n=79); and 87.3% for ABT-450 plus ritonavir, ABT-267 and ABT-333 (n=79). In null responders, ABT-450 plus ritonavir, ABT-267 and ribavirin for 12 weeks led to an SVR12 rate of 88.9% (n=45).
In treatment-naïve patients with HCV genotype 1a infection, SVR12 rates were 96% for ABT-450 plus ritonavir, ABT-267, ABT-333 and ribavirin for 12 weeks; 79% for ABT-450 plus ritonavir, ABT-333 and ribavirin for 12 weeks; 85% for ABT-450 plus ritonavir, ABT-267 and ribavirin for 12 weeks; 83% for ABT-450 plus ritonavir, ABT-267 and ABT-333 for 12 weeks; and 84% for ABT-450 plus ritonavir, ABT-267, ABT-333 and ribavirin for 8 weeks. In treatment-naïve patients with HCV genotype 1b infection, SVR12 rates were 100% for ABT-450 plus ritonavir, ABT-267, ABT-333 and ribavirin for 12 weeks; 100% for ABT-450 plus ritonavir, ABT-333 and ribavirin for 12 weeks; 100% for ABT-450 plus ritonavir, ABT-267 and ribavirin for 12 weeks; 96% for ABT-450 plus ritonavir, ABT-267 and ABT-333 for 12 weeks; and 96% for ABT-450 plus ritonavir, ABT-267, ABT-333 and ribavirin for 8 weeks. ...